The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC.

1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling!

2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease.

4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.

The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparison to the other BCMA-targeting CAR-T product, idi-cel and a recent comparison on plasma cell leukemia.

CARTITUDE-1 Long-Term F/U: https://doi.org/10.1200/JCO-25-00760

Cilta-cel & ide-cel in plasma cell leukemia: https://doi.org/10.1182/bloodadvances.2025016966

The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising study and its early, early results so far.

UF GBM study: https://doi.org/10.1016/j.cell.2024.04.003

RNA Treatment Vaccine Review: https://doi.org/10.1002/ctm2.1384

Malignant Hematology Updates:

Venetoclax dosing strategies continue to evolve

HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640

HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914

Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723

APOLLO: https://doi.org/10.1200/JCO-25-00535

Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496

ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.

Dordaviprone data: https://doi.org/10.1200/jco.23.01134

Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reaction rates and preventing potential medication errors in hematology-oncology: a randomized controlled trial. JCO Oncology Practice: https://doi.org/10.1200/OP-25-00158

More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.

ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf

RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

A brief overview of testicular cancer

A few supportive care updates:

1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.

Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode

Link: https://doi.org/10.1200/OP-25-00100

2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes

Link: https://doi.org/10.1016/S1470-2045(25)00231-1

Two new drug approvals to talk about (after I misplaced my notes!)